NGNE logo

NGNE Neurogene Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$23.90
-1.20 (-4.78%)

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 …

Market Cap: $377.68Mwww.neurogene.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
50
2 mentions
—
60d
50
3 mentions
—
90d
50
5 mentions
—
news: 5

Analyst Ratings

7 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 1Sell 0Strong Sell 0
Avg price target$72+201.3%
Low $65Median $70High $81
Current Consensus

Revenue

$0.00
$0.00$8.33M$16.67M$25.00M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-4.32
$-4.74–$-4.15
5 analysts
FY2026
$-5.31
$-5.68–$-4.76
3 analysts
FY2027
$-5.60
$-8.26–$-1.51
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Rachel L. McMinn
Sector
Healthcare
Industry
Biotechnology
Employees
131
Beta
2.09
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
8.20
www.neurogene.com